Iceland· IS-EU/1/14/922/001-003
Incruse Ellipta
A umeclidinium bromide product containing umeclidinii bromidum inn, registered in Iceland by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 12 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Umeclidinium bromide is registered in 12 of 19 countries.
Countries holding a registration under ATC R03BB07 (umeclidinium bromide), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Umeclidinium bromide · ATC R03BB07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of umeclidinium bromide costs, country by country.
Normalised to the WHO defined daily dose (55 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Umeclidinium bromide · price per daily dose (55 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$1.57
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Umeclidinii bromidum INN
- Manufacturer
- GlaxoSmithKline Trading Services Limited
- Country
- Iceland (IS)
- ATC code
- R03BB07
- ATC class
- Umeclidinium bromide
- Defined daily dose
- 55 mcg, Inhal
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean53871330 skammtar x1 innö.tISK 6821
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
114 interactions on record for umeclidinium bromide.
Graded by severity as the source publishes them — 113 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Umeclidinium bromide · interactions on record
114 records
- 113 moderate
- 1 minor
Most severe, free to view
- DicycloverineA03AA07moderate
- PropanthelineA03AB05moderate
- MepenzolateA03AB12moderate
- TrospiumA03AB20moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Umeclidinium bromide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomIncruse Ellipta 55micrograms/dose dry powder inhalerEthigen Ltd
- CzechiaINCRUSE ELLIPTAGlaxoSmithKline Trading Services Limited, Dublin
- BelgiumElebrato Ellipta 92 µg/dose - 22 µg/doseGlaxoSmithKline Trading Services
- SpainINCRUSE ELLIPTA 55 mcg POLVO PARA INHALACION UNIDOSISGlaxosmithkline Trading Services Limited
- FinlandIncruse ElliptaGlaxoSmithKline Trading Services Limited
- United StatesIncruse ElliptaGlaxoSmithKline LLC
- SwitzerlandIncruse Ellipta
- IrelandIncruse Ellipta 55 micrograms inhalation powder, pre-dispensedGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Incruse Ellipta, Rolufta Ellipta
- Norway · Incruse Ellipta, Rolufta Ellipta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d6dd68ae-5d2c-4746-9803-9b5e3691ace2 GET /v1/drugs/d6dd68ae-5d2c-4746-9803-9b5e3691ace2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innöndunarduft, afmældir skammtar",
"source": "lyfjastofnun",
"atc_raw": "R03BB07",
"marketed": true,
"strength": "55 míkróg",
"ma_number": "EU/1/14/922/001-003",
"substance": "Umeclidinii bromidum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt",
"ma_issued_serial": "41757"
}See everything about umeclidinium bromide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.